PCM
RYTM icon

Prelude Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Prelude Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,372
Closed -$728K – 1491
2026
Q1 		$728K Buy
+8,372
New +$814K 0.06% 380
2024
Q2 		– Sell
-10,706
Closed -$464K – 1464
2024
Q1 		$464K Sell
10,706
-6,700
-38% -$293K 0.02% 668
2023
Q4 		$800K Buy
17,406
+1,000
+6% +$31.5K 0.05% 354
2023
Q3 		$376K Buy
+16,406
New +$367K 0.02% 569
2019
Q3 		– Sell
-365
Closed -$8K – 1999
2019
Q2 		$8K Buy
+365
New +$9.22K ﹤0.01% 1439

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Prelude Capital Management's RYTM Position: Q2 2026 in Review

Prelude Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 8,372 shares — an estimated $728K sold.

Prelude Capital Management first reported a position in RYTM in Q2 2019 and held it in 5 quarters. The position peaked at $800K in Q4 2023. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Prelude Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 8,372 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $728K.
  • Prelude Capital Management first reported a position in Rhythm Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Prelude Capital Management's Rhythm Pharmaceuticals position peaked at $800K in Q4 2023.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.